Business

Aditxt to Establish State-of-the-Art Immune Monitoring Center in Richmond, VA

AditxtScore™ Center is the first of a planned immune monitoring network and will initially monitor COVID-19 immunity status New facility expects to target

articleAditxt, Inc.May 3, 20215/company/aditxt-inc/news/aditxt-to-establish-state-of-the-art-immune-monitoring-center-in-richmond-va
Aditxt to Establish State-of-the-Art Immune Monitoring Center in Richmond, VA

About this update from Aditxt, Inc.

[{"type":"text","content":"AditxtScore™ Center is the first of a planned immune monitoring network and will initially monitor COVID-19 immunity status\n New facility expects to target more than 300 jobs over three years to the area\n\n\nMOUNTAIN VIEW, Calif. and RICHMOND, Va., May 3, 2021 /PRNewswire/ -- Aditxt (Aditx Therapeutics, Inc.) (Nasdaq: ADTX), a biotech innovation company focused on improving the health of the immune system, today announced plans to build a high-capacity AditxtScore™ Center in Richmond, VA in the second half of 2021. Aditxt is targeting a capital investment of $31.5 million over three years to scale up its state-of-the-art immune monitoring center, including projected new jobs, laboratory equipment, and construction. The announcement was made at a joint press conference with Governor Ralph Northam, Richmond Mayor Levar Stoney and other local business executives and political officials. \n\n \n \n \n \n \n \n\n \nThe new immune monitoring center is being developed to increase processing capacity for the company's flagship AditxtScore™, a pioneering new approach to immune health monitoring that provides a comprehensive profile of the immune system. By assessing an individual's immune biomarkers, AditxtScore™ will be able to measure indications of immunity to specific disease. AditxtScore™ applications include the recently commercialized AditxtScore™ for COVID-19, developed for use in detecting antibodies and neutralizing antibodies against SARS-CoV-2 antigens. Other applications under development include, among others, predicting dynamic monitoring of the immune system in infectious and autoimmune diseases, organ transplantation, and allergy. \nAmro Albanna, co-founder and CEO of Aditxt, commented, \"Richmond is an ideal location for our first high-capacity AditxtScore Center given its skilled workforce, location, and infrastructure. As we begin rolling out the AditxtScore platform and applications for immune monitoring, the establishment of an AditxtScore Immune Monitoring Network is vital to realizing our full vision for AditxtScore, which is to transform how we monitor the immune system from reactive testing to proactive monitoring. We look forward to working with the community to complete this important step in the execution of Aditxt's strategic plan, and we are grateful to the Commonwealth of Virginia, Governor Northam, his ...

More updates from Aditxt, Inc.